The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
BUSINESS
Daiichi Sankyo Ramps Up R&D Investment for ADC, 16 Studies Added to DS-8201
Daiichi Sankyo will boost its R&D investment in antibody drug conjugates (ADCs), with CEO Sunao Manabe pledging to inject 1.1 trillion yen over five years (FY2018-FY2022) into three top-priority projects, DS-8201, DS-1062, and U3-1402. Mr Manabe unveiled this plan at…
To read the full story
Related Article
- Daiichi Sankyo Enjoys 7.7% Rise in April-December Sales; Enhertu Off to Solid Start
February 3, 2020
- Daiichi Sankyo Aims to Become Global Leader of ADCs: CEO
December 18, 2019
- Edoxaban Drives Daiichi Sankyo’s Half-Year Earnings
November 1, 2019
BUSINESS
- Tokyo Court Tosses Nihon Generic’s Suit over Bayer’s Xarelto Patent Communications
December 18, 2025
- Velcade Generics Widen Labels to Mantle Cell Lymphoma
December 18, 2025
- Kowa Releases Glaucoma Drug Gla-Alpha in Malaysia
December 18, 2025
- Xarelto Generics Win Adult, Pediatric VTE Indication Expansions
December 18, 2025
- AI-Driven Target Discovery Gains Ground among Japanese Pharma: FRONTEO CEO
December 17, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…